Stockreport

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech, Inc.  (IOBT) 
PDF Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembroliz [Read more]